Edinburgh Partners Ltd buys $75,757,923 stake in Celgene Corporation (CELG)

Celgene Corporation (CELG) : Edinburgh Partners Ltd scooped up 684,075 additional shares in Celgene Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 18, 2016. The investment management firm now holds a total of 685,468 shares of Celgene Corporation which is valued at $75,757,923.Celgene Corporation makes up approximately 8.31% of Edinburgh Partners Ltd’s portfolio.

Celgene Corporation opened for trading at $110.34 and hit $111.5 on the upside on Friday, eventually ending the session at $110.52, with a gain of 0.55% or 0.6 points. The heightened volatility saw the trading volume jump to 48,55,538 shares. Company has a market cap of $86,390 M.

Other Hedge Funds, Including , Cohen Klingenstein reduced its stake in CELG by selling 310 shares or 2.29% in the most recent quarter. The Hedge Fund company now holds 13,240 shares of CELG which is valued at $1,463,285. Celgene Corporation makes up approx 0.27% of Cohen Klingenstein’s portfolio.Kanaly Trust Co reduced its stake in CELG by selling 79 shares or 9.46% in the most recent quarter. The Hedge Fund company now holds 756 shares of CELG which is valued at $81,149. Celgene Corporation makes up approx 0.02% of Kanaly Trust Co’s portfolio.Exxonmobil Investment Management Inc Tx boosted its stake in CELG in the latest quarter, The investment management firm added 14,218 additional shares and now holds a total of 190,316 shares of Celgene Corporation which is valued at $20,428,519. Celgene Corporation makes up approx 0.46% of Exxonmobil Investment Management Inc Tx’s portfolio.First American Bank reduced its stake in CELG by selling 50,323 shares or 46.31% in the most recent quarter. The Hedge Fund company now holds 58,348 shares of CELG which is valued at $6,057,106. Celgene Corporation makes up approx 0.63% of First American Bank’s portfolio.

On the company’s financial health, Celgene Corporation reported $1.18 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on Jan 28, 2016. Analyst had a consensus of $1.21. The company had revenue of $2563.30 million for the quarter, compared to analysts expectations of $2548.22 million. The company’s revenue was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.01 EPS.

Many Wall Street Analysts have commented on Celgene Corporation. Citigroup Initiated Celgene Corporation on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $130.Shares were Reiterated by RBC Capital Mkts on Jan 29, 2016 to “Outperform” and Lowered the Price Target to $ 135 from a previous price target of $150 .Celgene Corporation was Initiated by Credit Suisse to “Outperform” on Jan 20, 2016.

Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

Leave a Reply

Celgene Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Celgene Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.